Scilex Holding Co (SCLX) - Dilution Analysis

S-3 filing: This filing registers the potential issuance of common stock underlying various outstanding warrants and a convertible note, as well as the resale of shares by selling securityholders.

10-Q filing | 8.5M shares outstanding

8-K filing: Scilex Holding Company's subsidiary, ACEA Therapeutics, Inc., entered into a Stock Acquisition Agreement with Phoenix Asia Holdings Limited, where ACEA Thera will transfer 100% of ACEA Pharma's shares in exchange for 100,000,000 newly-issued ordinary shares of Phoenix Asia at $10.00 per share. ($1000.0M proceeds)

S-3 filing: SCILEX HOLDING COMPANY is offering up to $500,000,000 in the aggregate of any combination of common stock, preferred stock, and debt securities.

8-K filing: Scilex Holding Company entered into a Non-Recourse Loan and Securities Pledge Agreement with The St. James Bank & Trust Company Ltd., pledging approximately 39.2 million shares of Datavault AI Inc. common stock as security for a loan of up to $50 million.

10-Q filing | 7.6M shares outstanding

8-K filing: Scilex Holding Company, along with Scilex, Inc., sold 12,500,000 shares of Semnur Pharmaceuticals, Inc. common stock to Biconomy PTE.LTD for $16.00 per share, with the transaction closing on September 25, 2025. ($200.0M proceeds)

8-K filing: Scilex Holding Company entered into a Securities Purchase Agreement with Datavault AI Inc. to purchase 15.0 million shares of Datavault Common Stock and a pre-funded warrant to purchase 263,914,094 shares of Datavault Common Stock for $150 million; 15.0 million shares were issued on September 26, 2025 at $0.5378 per share. ($149.97M proceeds)

10-Q filing | 7.0M shares outstanding

S-1 filing: This S-1 filing registers the resale of common stock by a selling stockholder, with the company having the option to sell shares to the stockholder under a purchase agreement.

10-Q filing | 7.0M shares outstanding

POS AM filing: This POS AM filing relates to the issuance of up to 3,593,288 shares of common stock upon exercise of warrants and conversion of notes, and the offer and sale of up to 3,250,000 shares of common stock by the Selling Securityholder upon exercise of a warrant.

POS AM filing: This is a POS AM filing to register the issuance of common stock upon exercise of warrants, and the resale of common stock and warrants by selling securityholders.

POS AM filing: This prospectus relates to the offer and sale from time to time by the Selling Stockholder of up to an aggregate of 6,685,714 shares of Common Stock, consisting of (i) up to 6,500,000 Penny Warrant Shares and (ii) up to 185,714 Issued Shares.

10-K filing | 243.3M shares outstanding

10-Q filing | 243.3M shares outstanding

8-K filing: Scilex Holding Company entered into a Letter Agreement with Oramed Pharmaceuticals Inc. on September 20, 2024, regarding a Senior Secured Promissory Note and warrants, including an agreement for Oramed to purchase the Purchased Warrants for $300,000 and the ability to immediately exercise the CS-5 Warrant for up to 1,062,500 shares of Common Stock. ($0.3M proceeds)

10-Q filing | 191.8M shares outstanding

S-3 filing: This is an S-3 filing for the resale of common stock by selling securityholders.

10-Q filing | 181.2M shares outstanding

POS AM filing: This is a POS AM filing for the offer and sale from time to time by the selling stockholders of up to 69,738,977 shares of common stock, the issuance by the company of up to 10,958,309 shares of common stock upon exercise of warrants, and the offer and sale from time to time by the selling warrantholders of up to 5,402,955 warrants.

POS AM filing: This is a Post-Effective Amendment to deregister 2,657,569 Conversion Shares that are issuable upon the conversion of Convertible Debentures as the company has fully repaid the Convertible Debentures and terminated the offering.

POS AM filing: Scilex Holding Company is removing 16,429,616 shares of common stock from registration after terminating the amended and restated standby equity purchase agreement.

POS AM filing: This is a filing for the resale of up to 13,324,683 shares of common stock by selling stockholders, including shares issued under a settlement agreement and shares issuable upon exercise of warrants.

10-K filing | 166.2M shares outstanding

POS AM filing: This is a deregistration of unsold securities related to a standby equity purchase agreement.

S-3/A filing: SCILEX HOLDING COMPANY files an S-3/A form to offer and sell up to $500,000,000 in the aggregate of common stock, preferred stock, and debt securities.

S-3 filing: SciLex Holding Company is filing an S-3 to offer and sell up to $500,000,000 in the aggregate of any combination of common stock, preferred stock, and debt securities.

S-1/A filing: This S-1/A filing registers the resale of up to 13,474,683 shares of common stock by selling stockholders, including shares issued under a Settlement Agreement and shares issuable upon exercise of warrants.

10-Q filing | 155.9M shares outstanding

S-1/A filing: This prospectus relates to the resale from time to time by the selling stockholders of up to an aggregate of 13,474,683 shares of our common stock.

S-1 filing: This S-1 filing is for the issuance of up to 13,000,000 shares of common stock issuable upon the exercise of warrants and the offer and sale of up to 13,474,683 shares of common stock by selling stockholders.

RW filing: Scilex Holding Company is requesting to withdraw their Registration Statement on Form S-1 (File No. 333-271401) because they have decided not to pursue the offering due to market conditions.

10-Q filing | 142.6M shares outstanding

S-1/A filing: Scilex Holding Company is offering 13,274,336 shares of its common stock at an assumed public offering price of $5.65 per share.

S-1/A filing: This is an S-1/A filing for a common stock offering to be used for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock.

S-1/A filing: SCILEX HOLDING COMPANY is offering shares of its common stock at an assumed public offering price based upon the last reported sale price of its Common Stock on the Nasdaq Capital Market on June 28, 2023.

S-1/A filing: SCILEX HOLDING COMPANY is offering shares of its common stock at an assumed public offering price based upon the last reported sale price of its Common Stock on the Nasdaq Capital Market on May, 2023.

S-1/A filing: SCILEX HOLDING COMPANY is offering shares of its common stock at an assumed public offering price based upon the last reported sale price of its Common Stock on the Nasdaq Capital Market on June 2, 2023, which was $6.41.

S-1/A filing: SCILEX HOLDING COMPANY is offering shares of its common stock with a total proposed amount of $75,000,000, based upon the last reported sale price of its Common Stock on the Nasdaq Capital Market on May 22, 2023, which was $7.84 per share.

10-Q filing | 141.7M shares outstanding

S-1 filing: Scilex Holding Company registers the offer and sale of up to 3,290,000 shares of common stock by YA II PN, Ltd. upon conversion of convertible debentures.

POS AM filing: This POS AM filing registers the resale of up to 71,459,469 shares of common stock by selling stockholders and warrantholders, as well as the issuance of up to 11,003,988 shares of common stock upon the exercise of warrants.

POS AM filing: This prospectus relates to the resale from time to time of up to 28,078,672 shares of common stock of Scilex Holding Company by YA II PN, Ltd.

POS AM filing: This prospectus relates to the resale from time to time of up to 28,128,422 shares of common stock by B. Riley Principal Capital II, LLC pursuant to a standby equity purchase agreement, where Scilex has committed to sell up to $500,000,000 of common stock to B. Riley.

10-K filing | 145.8M shares outstanding

S-1 filing: Scilex Holding Company is filing an S-1 to register the resale of up to 28,128,422 shares of common stock by B. Riley Principal Capital II, LLC, which includes shares issued as a commitment and shares that may be issued under a purchase agreement, potentially generating up to $500,000,000 in gross proceeds for the company.

S-1/A filing: This S-1/A filing relates to the issuance of up to 11,003,988 shares of common stock upon exercise of warrants and the offer and sale of up to 145,200,264 shares of common stock and warrants by selling securityholders.

S-1 filing: This S-1 filing covers the offer and sale of up to 144,975,423 shares of common stock by selling stockholders, the issuance of up to 11,003,988 shares of common stock upon the exercise of warrants, and up to 5,265,776 warrants.

S-1 filing: This S-1 filing relates to the resale from time to time of up to 28,078,672 shares of common stock of Scilex Holding Company by YA II PN, Ltd., and also the potential issuance and sale of up to $500,000,000 of common stock to YA II PN, Ltd. under a standby equity purchase agreement.

10-Q filing | 13.2M shares outstanding

10-Q filing | 13.2M shares outstanding

8-K filing: Vickers Vantage Corp. I amended its Amended and Restated Memorandum and Articles of Association to extend the date to consummate an initial business combination, and 4,073,605 ordinary shares were redeemed at $10.25 per share, resulting in approximately $41.8 million being removed from the trust account. ($41.8M proceeds)

10-Q filing | 17.3M shares outstanding

10-K filing | 16.8M shares outstanding

10-Q filing | 17.3M shares outstanding

10-Q filing | 23.7M shares outstanding

10-Q filing | 17.3M shares outstanding

10-K filing | 17.3M shares outstanding

8-K filing: Vickers Vantage Corp. I consummated an IPO of 13,800,000 units at $10.00 per unit, generating gross proceeds of $138,000,000 and consummated a private placement of 6,840,000 warrants at $0.75 per warrant, generating gross proceeds of $5,130,000. ($143.13M proceeds)

S-1/A filing: The company is offering an over-allotment option to purchase up to an additional 1,500,000 units at $10.00 per unit.

S-1 filing: S-1 filing for units consisting of ordinary shares and warrants.